英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
knirschen查看　knirschen　在百度字典中的解释百度英翻中〔查看〕
knirschen查看　knirschen　在Google字典中的解释Google英翻中〔查看〕
knirschen查看　knirschen　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • ADSTILADRIN® (nadofaragene firadenovec-vncg) | For HCP
    Nadofaragene firadenovec- vncg (ADSTILADRIN) is A recommended treatment option: In the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)* and the AUA SUO Guidelines1 By the International Bladder Cancer Group (IBCG) for high-risk NMIBC after BCG failure for those seeking to avoid radical cystectomy 2
  • Package Insert and Information for Patients - Adstiladrin
    ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive
  • Adstiladrin | European Medicines Agency (EMA)
    The active substance of Adstiladrin is nadofaragene firadenovec, an antineoplastic cell and gene therapy (ATC code: L01XL10) Nadofaragene firadenovec is a non-replicating, recombinant type 5 adenovirus vector-based gene therapy containing the human IFNα2b transgene
  • Adstiladrin: Uses, Dosage, Side Effects Warnings - Drugs. com
    Adstiladrin (nadofaragene firadenovec-vncg) is a gene therapy used to treat high-risk Bacillus CalmetteGuérin (BCG)-unresponsive non-muscle invasive bladder cancer Includes Adstiladrin side effects, interactions and indications
  • Nadofaragene firadenovec - Wikipedia
    Nadofaragene firadenovec, sold under the brand name Adstiladrin, is a gene therapy for the treatment of bladder cancer [1][3][4] It is a non-replicating (cannot multiply in human cells) adenoviral vector-based gene therapy
  • ADSTILADRIN® (nadofaragene firadenovec-vncg) | NMIBC Treatment
    ADSTILADRIN® is the first and only FDA-approved gene therapy for treating adult patients with high-risk BCG-unresponsive NMIBC See Important Safety Info
  • FDA Approval Summary: Nadofaragene firadenovec-vncg for . . .
    The approval of nadofaragene firadenovec provides a new therapy option for patients with BCG-unresponsive NMIBC with CIS who are ineligible for cystectomy Introduction On December 16, 2022, FDA approved nadofaragene firadenovec (brand name Adstiladrin), the first gene therapy for the treatment of bladder cancer
  • Nadofaragene firadenovec-vncg (urinary bladder route)
    Description Nadofaragene Firadenovec-vncg is used to treat patients with high-risk Bacillus Calmette-Guerin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with a tumor type called carcinoma in situ (CIS) with or without papillary tumors This medicine is to be used only by or under the direct supervision of a doctor
  • Ferring Highlights New Real-World Research with ADSTILADRIN . . .
    About ADSTILADRIN ADSTILADRIN ® (nadofaragene firadenovec-vncg) is the first and only FDA-approved intravesical non-replicating gene-therapy for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors
  • ADSTILADRIN | FDA
    STN: BLA 125700 Proper Name: nadofaragene firadenovec-vncg Tradename: ADSTILADRIN Manufacturer: Ferring Pharmaceuticals A S Indication: ADSTILADRIN is indicated for the treatment of adult patients





中文字典-英文字典  2005-2009